Please check your internet connection and try again.
# Tab-genixim
## Overview
Tab-genixim is a brand name for a hypothetical third-generation cephalosporin antibiotic. It is intended for the treatment of bacterial infections.
## Primary Indications
* **Community-Acquired Pneumonia (CAP):** Caused by susceptible organisms.
* **Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB):** Caused by susceptible organisms.
* **Acute Maxillary Sinusitis:** Caused by susceptible organisms.
## Adult Dosing
* **CAP & ABECB:** 500 mg orally every 12 hours for 5-7 days.
* **Acute Maxillary Sinusitis:** 500 mg orally every 12 hours for 10 days.
Maximum daily dose: 1000 mg.
## Pediatric Dosing
Dosing for pediatric patients is not established for this hypothetical drug. Use with caution and consult specialized pediatric infectious disease resources.
## Dose Adjustments
* **Renal Impairment:**
* CrCl 30-49 mL/min: 500 mg orally every 24 hours.
* CrCl < 30 mL/min: 500 mg orally every 48 hours.
Dialysis patients: consult prescribing information for specific recommendations.
## Contraindications
* Hypersensitivity to tab-genixim, other cephalosporins, or any component of the formulation.
* History of severe hypersensitivity reaction (e.g., anaphylaxis) to penicillin or other beta-lactam antibiotics.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures (rare, particularly with renal impairment and high doses).
## Key Drug Interactions
* **Probenecid:** May increase and prolong serum concentrations of tab-genixim.
* **Oral Contraceptives:** Efficacy may be reduced. Advise alternative or additional non-hormonal contraception.
## Monitoring
* Monitor for signs and symptoms of bacterial infection; clinical improvement should be observed within 2-3 days of initiating therapy.
* Monitor for signs of hypersensitivity reactions.
* Monitor for diarrhea; if *C. difficile*-associated diarrhea is suspected, discontinue tab-genixim and institute appropriate therapy.
* Renal function should be assessed periodically in patients with known or suspected renal impairment.
## Clinical Pearls
* Tab-genixim has broad-spectrum activity against many Gram-positive and Gram-negative pathogens.
* Ensure gastric decontamination is not performed if a rapid diagnostic test for *C. difficile* is to be performed, as this can lead to false-negative results.
* Should be taken with or without food.
***
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. The clinical pharmacist strongly recommends that all prescribers consult the official prescribing information and relevant guidelines for the most current and comprehensive drug details before making any treatment decisions. Drug availability and specific formulations may vary.
